{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-060121","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2024-07-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:15.952646+00:00","generated_at":"2026-05-31T22:42:19.962498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ImmuCell reports preliminary Q2 sales of $5.47M, up 55% YoY; H1 sales up 82%","bullets":["Q2 2024 preliminary sales $5.47M vs $3.53M in Q2 2023, a 55% increase.","Six-month sales $12.73M, up 82% from $6.98M; twelve-month sales $23.22M, up 48%.","Backlog of orders as of June 30, 2024: approx. $8.93M.","Production output at 74% of $30M full capacity in Q2; goal to produce $14M in H2 to reach ~95%.","Still working on FDA approval for Re-Tain; expect fourth CMC submission after manufacturer issues resolved."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-060121","json":"https://secwatch.observer/filing/0001213900-24-060121.json","markdown":"https://secwatch.observer/filing/0001213900-24-060121.md","text":"https://secwatch.observer/filing/0001213900-24-060121.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000121390024060121/0001213900-24-060121-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000121390024060121/ea0209162-8k_immucell.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T22:42:19.962498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}